|
KMID : 1142120180200020258
|
|
Journal of Stroke
2018 Volume.20 No. 2 p.258 ~ p.267
|
|
|
Differences in Therapeutic Responses and Factors Affecting Post-Stroke Depression at a Later Stage According to Baseline Depression
|
|
Lee Eun-Jae
Kim Jong-S.
Chang Dae-Il
Park Jong-Ho
Ahn Seong-Hwan
Cha Jae-Kwan
Heo Ji-Hoe
Sohn Sung-Il
Lee Byung-Chul
Kim Dong-Eog
Kim Hahn-Young
Kim Seong-Heon
Kwon Do-Young
Kim Jei
Seo Woo-Keun
Lee Jun
Park Sang-Won
Koh Seong-Ho
Kim Jin-Young
Choi-Kwon Smi
Kim Min-Sun
Lee Ji-Sung
|
|
|
Abstract
|
|
|
Background and Purpose: The pathophysiology of post-stroke depression (PSD) is complex and may differ according to an individual’s mood immediately after stroke. Here, we compared the therapeutic response and clinical characteristics of PSD at a later stage between patients with and without depression immediately after stroke.
Methods: This study involved a post hoc analysis of data from EMOTION (ClinicalTrials.gov NCT01278498), a placebo-controlled, double-blind trial that examined the efficacy of escitalopram (10 mg/day) on PSD and other emotional disturbances among 478 patients with acute stroke. Participants were classified into the Baseline-Blue (patients with baseline depression at the time of randomization, defined per the Montgomery-Asberg Depression Rating Scale [MADRS] ≥8) or the Baseline-Pink groups (patients without baseline depression). We compared the efficacy of escitalopram and predictors of 3-month PSD (MADRS ≥8) between these groups.
Results: There were 203 Baseline-Pink and 275 Baseline-Blue patients. The efficacy of escitalopram in reducing PSD risk was more pronounced in the Baseline-Pink than in the Baseline-Blue group (p for interaction=0.058). Several risk factors differentially affected PSD development based on the presence of baseline depression (p for interaction <0.10). Cognitive dysfunction was an independent predictor of PSD in the Baseline-Blue, but not in the Baseline-Pink group, whereas the non-use of escitalopram and being female were more strongly associated with PSD in the Baseline-Pink group.
Conclusions: Responses to escitalopram and predictors of PSD 3 months following stroke differed based on the presence of baseline depression. Our data suggest that PSD pathophysiology is heterogeneous; therefore, different therapeutic strategies may be needed to prevent PSD emergence following stroke.
|
|
|
KEYWORD
|
|
|
Depression, Stroke, Escitalopram, Anger, Emotional incontinence
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
   
|